Daniel Karlin
CIK 1897618 · Chief Medical Officer · last filed 2026-06-26
Daniel Karlin is a Chief Medical Officer who has filed 43 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing shows the insider sold $451.9K of DFTX on Jun 26, 2026. Across all open-market trades the lifetime net is −$1.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $22.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$22.34M
2
43
-$1.21M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Medical Officer | 503,282 | $44.39 | $22.34M | -$600.0K | 4 | 2026-06-26 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Medical Officer | 425,025 | $15.00 | $6.38M | -$607.6K | 27 | 2025-12-29 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | DFTX | Sell (S) | −10,035 | -$451.9K | EDGAR |
| 2026-06-25 | DFTX | Notice (144) | −10,035 | -$422.8K | EDGAR |
| 2026-06-22 | DFTX | Grant (A) | +100,000 | $0 | EDGAR |
| 2026-03-26 | DFTX | Sell (S) | −8,018 | -$148.1K | EDGAR |
| 2026-03-25 | DFTX | Notice (144) | −8,018 | -$148.1K | EDGAR |
| 2026-02-05 | DFTX | Grant (A) | +150,000 | $0 | EDGAR |
| 2025-12-29 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −5,600 | -$73.6K | EDGAR |
| 2025-12-29 | DFTX | Notice (144) | −5,600 | -$73.6K | EDGAR |
| 2025-09-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −7,704 | -$75.3K | EDGAR |
| 2025-09-25 | DFTX | Notice (144) | −7,704 | -$75.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.